Chembio Diagnostics Inc. [NASDAQ: CEMI] loss -5.03% on the last trading session, reaching $8.50 price per share at the time. Chembio Diagnostics Inc. represents 17.20 million in outstanding shares, while the company has a total market value of $174.76 million with the latest information. CEMI stock price has been found in the range of $8.205 to $8.733.
If compared to the average trading volume of 1.37M shares, CEMI reached a trading volume of 1018025 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here is what top equities market gurus are saying about Chembio Diagnostics Inc. [CEMI]:
Robert W. Baird have made an estimate for Chembio Diagnostics Inc. shares, keeping their opinion on the stock as Outperform, with their previous recommendation back on May 26, 2020. While these analysts kept the previous recommendation, The Benchmark Company dropped their target price from $9 to $6. The new note on the price target was released on March 04, 2020, representing the official price target for Chembio Diagnostics Inc. stock. Previously, the target price had yet another drop from $9 to $5, while The Benchmark Company kept a Speculative Buy rating on CEMI stock.
The Average True Range (ATR) for Chembio Diagnostics Inc. is set at 1.07, with the Price to Sales ratio for CEMI stock in the period of the last 12 months amounting to 5.30. The Price to Book ratio for the last quarter was 8.10, with the Price to Cash per share for the same quarter was set at 0.54.
Trading performance analysis for CEMI stock
Chembio Diagnostics Inc. [CEMI] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 1.67. With this latest performance, CEMI shares dropped by -26.22% in over the last four-week period, additionally plugging by 99.06% over the last 6 months – not to mention a rise of 39.34% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for CEMI stock in for the last two-week period is set at 42.14, with the RSI for the last a single of trading hit 37.83, and the three-weeks RSI is set at 44.35 for Chembio Diagnostics Inc. [CEMI]. The present Moving Average for the last 50 days of trading for this stock 10.68, while it was recorded at 8.63 for the last single week of trading, and 6.24 for the last 200 days.
Chembio Diagnostics Inc. [CEMI]: A deeper dive into fundamental analysis
Operating Margin for any stock indicates how profitable investing would be, and Chembio Diagnostics Inc. [CEMI] shares currently have an operating margin of -36.58 and a Gross Margin at +35.02. Chembio Diagnostics Inc.’s Net Margin is presently recorded at -39.68.
Return on Total Capital for CEMI is now -30.26, given the latest momentum, and Return on Invested Capital for the company is -33.22. Return on Equity for this stock declined to -47.68, with Return on Assets sitting at -24.65. When it comes to the capital structure of this company, Chembio Diagnostics Inc. [CEMI] has a Total Debt to Total Equity ratio set at 106.41. Additionally, CEMI Total Debt to Total Capital is recorded at 51.55, with Total Debt to Total Assets ending up at 36.51. Long-Term Debt to Equity for the company is recorded at 103.12, with the Long-Term Debt to Total Capital now at 49.96.
Reflecting on the efficiency of the workforce at the company, Chembio Diagnostics Inc. [CEMI] managed to generate an average of -$42,207 per employee. Receivables Turnover for the company is 6.25 with a Total Asset Turnover recorded at a value of 0.62.Chembio Diagnostics Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 2.10 and a Current Ratio set at 3.50.
Chembio Diagnostics Inc. [CEMI]: An earnings per share (EPS) analysis
With the latest financial reports released by the company, Chembio Diagnostics Inc. posted -0.19/share EPS, while the average EPS was predicted by analysts to be reported at -0.15/share.When compared, the two values demonstrate that the company fail the estimates by a Surprise Factor of -26.70%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for CEMI. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Chembio Diagnostics Inc. go to 25.00%.
An analysis of insider ownership at Chembio Diagnostics Inc. [CEMI]
There are presently around $70 million, or 41.30% of CEMI stock, in the hands of institutional investors. The top three institutional holders of CEMI stocks are: NANTAHALA CAPITAL MANAGEMENT, LLC with ownership of 1,432,032, which is approximately 15.488% of the company’s market cap and around 0.20% of the total institutional ownership; ROYCE & ASSOCIATES LP, holding 1,175,316 shares of the stock with an approximate value of $10.52 million in CEMI stocks shares; and CORTINA ASSET MANAGEMENT, LLC, currently with $7.24 million in CEMI stock with ownership of nearly -0.73% of the company’s market capitalization.
28 institutional holders increased their position in Chembio Diagnostics Inc. [NASDAQ:CEMI] by around 1,733,294 shares. Additionally, 19 investors decreased positions by around 1,969,543 shares, while 6 investors held positions by with 4,097,354 shares. The mentioned changes placed institutional holdings at 7,800,191 shares, according to the latest SEC report filing. CEMI stock had 13 new institutional investments in for a total of 1,257,580 shares, while 10 institutional investors sold positions of 1,661,801 shares during the same period.